Sung Lim
Rheumatology · Atlanta, GANPI 1366558744
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $119,522 of the $124,926 with a category attached, or 95.7%. 13 manufacturers reported payments, led by GSK at 25.3% of the total. Among rheumatology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 97 payments — averaging $1287.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$32K
- AstraZeneca$27K
- E.r. Squibb & Sons, L.L.C.$12K
- UCB, Inc.$12K
- UCB SA$12K
- Pfizer$10K
- plus $21K from 7 others
Across 103 payments — averaging $11,846 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$426K
- AstraZeneca$290K
- UCB SA$213K
- Astrazeneca UK Limited$123K
- Genentech, Inc.$68K
- Novartis$48K
- plus $52K from 3 others
What the payments were for
- Consulting fees$119,52296%
- Travel & lodging$3,5213%
- Food & beverage$1,8842%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 25 | $31,550 |
| AstraZeneca | 24 | $27,494 |
| E.r. Squibb & Sons, L.L.C. | 9 | $11,738 |
| UCB, Inc. | 5 | $11,655 |
| UCB SA | 6 | $11,525 |
| Pfizer | 2 | $10,000 |
| Astrazeneca UK Limited | 2 | $7,384 |
| F. Hoffmann-la Roche AG | 4 | $4,981 |
| Biogen | 14 | $4,004 |
| UCB GmbH | 3 | $2,013 |
| Janssen Research & Development, LLC | 1 | $1,860 |
| Genentech, Inc. | 1 | $575 |
| Genentech USA, Inc. | 1 | $147 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$124,926 in reported general payments places this provider in the 90th percentile of 177 rheumatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 87 | $587,905 |
| Humira(Cf) PenAdalimumab | 46 | $416,363 |
| Enbrel SureclickEtanercept | 41 | $286,742 |
| Orencia ClickjectAbatacept | 11 | $58,638 |
| Mycophenolate Mofetil | 42 | $7,478 |
| Hydroxychloroquine Sulfate | 242 | $6,724 |
| MethotrexateMethotrexate Sodium | 213 | $3,417 |
| Leflunomide | 49 | $2,608 |
| Esomeprazole Magnesium | 14 | $1,213 |
| Prednisone | 189 | $1,035 |
| Azathioprine | 38 | $947 |
| Sulfasalazine | 30 | $628 |
| Diclofenac Sodium | 20 | $577 |
| Alendronate Sodium | 45 | $318 |
| Gabapentin | 29 | $184 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Atlanta
- Gary MyersonAtlanta$1M
- William WilsonAtlanta$344K
- Paul SutejAtlanta$140K
- Arezou KhosroshahiAtlanta$66K
- Kimberley WilsonAtlanta$41K
- John GoldmanAtlanta$33K
- Wambui MachuaAtlanta$31K
- Paula TanasaAtlanta$31K
- Rattandeep SinghAtlanta$20K
- Elizabeth ButlerAtlanta$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.